Delayed doxorubicin induced cardiomyopathy in a breast cancer patient: A case report
Case Reports
. 2023 Jan 13;18(3):1256-1260.
doi: 10.1016/j.radcr.2022.12.048.
eCollection 2023 Mar.
Affiliations
Item in Clipboard
Case Reports
Radiol Case Rep.
.
Abstract
Heart failure (HF) is a clinical syndrome with a wide spectrum of presentations and an even wider array of etiologies. Anthracyclines such as Doxorubicin, Daunorubicin, Idarubicin, and Epirubicin have demonstrated increased risk of HF with significant morbidity and mortality. We present an interesting case report of a patient with a history of breast cancer treated with Doxorubicin who presented with symptoms of HF who had a comprehensive evaluation that excluded the most common etiologies, narrowing our diagnosis to late onset doxorubicin induced HF with on-going recovery after initiation of guideline-directed medical therapy.
Keywords:
Breast cancer; Cardiomyopathy; Chemotherapy; Doxorubicin; Heart failure.
© 2022 The Authors. Published by Elsevier Inc. on behalf of University of Washington.
Figures
Fig. 1
Chest radiography (CXR) showing pulmonary vascular congestion and enlarged cardiac silhouette.
Fig. 2
Twelve-lead electrocardiogram showing T-wave inversions in leads V4-V6, left ventricular hypertrophy and J-point elevation in lead V3.
Fig. 3
(A) Parasternal long axis view showing anteroseptal and inferolateral hypokinesis and moderately dilated left atrium. (B) Apical 4-chamber view showing inferoseptal and anterolateral hypokinesis with LVEF of 10%.
References